2minutemedicine.com
Mirikizumab is safe and effective in patients with moderate-to-severe Crohn's disease
This trial suggests a new IL‑23 inhibitor, mirikizumab, may be an effective and safe treatment option for adults with moderate-to-severe Crohn's disease who have not responded to prior therapies. Positive phase 3 results could expand treatment choices for people with hard-to-treat disease.
Adults with moderate-to-severe Crohn's disease, patients considering or currently on biologic therapy, gastroenterologists, and IBD researchers.
What To Know
What To Know This article summarizes a large randomized controlled trial reported in The Lancet testing mirikizumab (an IL‑23p19 monoclonal antibody) in adults with moderate-to-severe Crohn's disease who had inadequate response or intolerance to prior therapies.
The trial found that a composite outcome of patient-reported clinical response (week 12) plus endoscopic response (week 52) was significantly greater with mirikizumab than placebo, and clinical remission at week 52 favored mirikizumab. Safety was reported as acceptable in this summary, and the authors note the trial was large and international.
The article also points out a limitation: reliance on non-responder imputation, which can influence estimated treatment effects. If you want original details (exact endpoints, dosing, adverse events, and subgroup results), consult the full Lancet paper linked in the story or discuss with your clinician.
This news piece is a study summary and does not replace medical advice.
The article is a secondary summary of a Lancet randomized controlled trial; it reports primary and key secondary outcomes but does not provide full safety or subgroup data. Non-responder imputation was used, which can affect real-world applicability. No immediate treatment changes are implied without clinician discussion and full trial review.
